agenT-797,pembrolizumab,nivolumab
mink therapeutics,bms,merck
['ability,(-inability)', 'agent']
stay tuned for mink s #sitc2022 presentation, with dr. terese hammond. this features new data on agent-797 in viral ards, which demonstrated encouraging survival and disease-mitigating benefits with a favorable tolerability profile. find out more during her presentation nov 10th! 